Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Reviva Pharmaceuticals Holdings ( (RVPH) ) has shared an announcement.
On September 18, 2025, Reviva Pharmaceuticals Holdings announced a registered public offering of 27 million shares of common stock and accompanying warrants, expected to raise approximately $8.1 million after expenses. The proceeds will fund research and development and general corporate purposes, with the offering expected to close around September 22, 2025, subject to customary conditions.
The most recent analyst rating on (RVPH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.
Spark’s Take on RVPH Stock
According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.
Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.
To see Spark’s full report on RVPH stock, click here.
More about Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for diseases with unmet medical needs. The company’s pipeline targets central nervous system, inflammatory, and cardiometabolic diseases, with drug candidates like brilaroxazine and RP1208.
Average Trading Volume: 2,711,583
Technical Sentiment Signal: Sell
Current Market Cap: $27.49M
Find detailed analytics on RVPH stock on TipRanks’ Stock Analysis page.